^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VBI-1901

    i
    Company:
    Brii Biosci, VBI Vaccines
    Drug class:
    Immunostimulant
    Related drugs:
    Apply
    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (NCT03382977)
    Phase 1/2
    VBI Vaccines Inc.
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/06/2017
    Primary completion :
    07/01/2025
    Completion :
    08/01/2025
    MGMT
    |
    lomustine • carmustine • VBI-1901